IGC Pharma's IGC-AD1 Shows Positive Results In Alzheimer’s Phase 2 Trial

IGC Pharma, Inc.,  has shared additional interim findings from its ongoing Phase 2 clinical trial of IGC-AD1, a treatment under investigation for addressing agitation in Alzheimer’s patients. The primary outcome of the study focuses on agitation, with cognitive improvement as an exploratory measure. Preliminary analysis shows significant cognitive improvements in the treatment group compared to placebo, bringing hope for a therapy that could influence the course of the disease.

These results are consistent with earlier preclinical data, which showed a 20% reduction in amyloid plaque aggregation and a 50% improvement in spatial memory in cell and animal models. In the current trial, participants receiving IGC-AD1 twice daily for six weeks showed an average 8% improvement on the Mini-Mental State Examination (MMSE), a standard cognitive assessment tool, while the placebo group saw no change.

Ram Mukunda, CEO of IGCPharma, said, “The cognitive improvements observed in our interim results align with preclinical evidence of IGC-AD1’s active pharmaceutical ingredients’ impact on amyloid plaques and spatial memory. While agitation remains the primary focus of the Phase 2 trial, these exploratory findings strengthen our confidence in IGC-AD1’s potential to address the broader pathology of Alzheimer’s disease. For patients and caregivers, this potentially represents hope for improved care, and for our investors, it signifies a compelling opportunity in a growing market.“ 

He also commented, “These developments aim to advance IGC-AD1 toward commercialisation with more trials and regulatory approvals, potentially delivering transformative patient care while creating significant value for our investors.”

The findings provide a strong foundation for future trials to make cognition a primary endpoint and further investigate IGC-AD1’s potential as a disease-modifying treatment. Agitation, a severe symptom affecting up to 76% of Alzheimer’s patients, accelerates disease progression, burdens caregivers, and often leads to hospitalisation. Previous interim results showed IGC-AD1 significantly reduced agitation, with improvements evident within two weeks, much faster than existing treatments, which typically require 6–10 weeks to take effect and come with safety concerns like black box warnings. IGC-AD1 has demonstrated a favourable safety profile, distinguishing it as a promising option for managing agitation in Alzheimer’s.

With Alzheimer’s disease affecting 6.7 million Americans and a global treatment market projected to surpass $50 billion by 2025, IGC-AD1’s dual benefits, rapid relief from agitation and potential disease-modifying properties position it as a groundbreaking therapy in this growing field.